ALVIMOPAN

Post-LOE

alvimopan

ANDAORALCAPSULE
Approved
Aug 2023
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
15

Mechanism of Action

µ-opioid receptor with a Ki of 0.4 nM (0.2 ng/mL) and no measurable opioid-agonist effects in standard pharmacologic assays. The dissociation of [ H]-alvimopan from the human µ-opioid receptor is slower than that of other opioid ligands, consistent with its higher affinity for the receptor. At…

Clinical Trials (5)

NCT03216525Phase 3Recruiting

Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

Started Oct 2018
136 enrolled
Bladder Cancer
NCT03068975Phase 4Terminated

Alvimopan Use in Polytraumatized Patients

Started Sep 2017
3 enrolled
Post Operative Ileus
NCT02789111Phase 4Completed

Trial of Alvimopan in Major Spine Surgery

Started Jun 2016
49 enrolled
Constipation
NCT02742181Phase 3Terminated

Alvimopan as Rescue in Post op Ileus

Started Dec 2015
14 enrolled
Colorectal SurgeryIleus
NCT01143259N/ACompleted

Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use

Started May 2010
Ileus